ASPIRE-ICU Study Reaches 1000 Inclusions!

A very important milestone was achieved in COMBACTE-NET‘s ASPIRE-ICU study: 1000 subjects were included to date in the study!

On the 28^th of August the ASPIRE-ICU reached the 50% enrollment, now having included 1000 subjects in the study. The team would like to congratulate everyone working on this exciting trial and wish them good luck in reaching the complete enrollment!

The figures below indicate that subjects have been recruited in 11 countries in Europe. When looking at a more regional level, most subjects have been enrolled in the Southern and Western part of Europe.

ASPIRE-ICU is a prospective, observational, multicenter, epidemiologic cohort study. Nested within routine surveillance among ICU patients in Europe. Aimed at the advanced understanding of Staphylococcus aureus and Pseudomonas aeruginosa infections in Europe (ASPIRE).

ASPIRE-ICU will be conducted at some twenty sites in ten European countries. After providing consent, a group of 2000 eligible patients will be enrolled as subjects. Together they form a study cohort where active sampling and more elaborate data collection will take place. Participants will be actively recruited for participation upon ICU admission. And will be followed for a certain period of time to determine the frequency of infections. Samples that will be collected are bacterial isolates and serum samples for in-depth microbiological and immunological testing.